Reviewer’s report

Title: Validation of the CancerMath prognostic tool for breast cancer in Southeast Asia

Version: 1 Date: 01 Jul 2016

Reviewer: Dongfeng Wu

Reviewer's report:

This is a well written paper on the validation of CancerMath, an existing web based prognostic tool, posted by a research group in the US.

The authors did a thorough evaluation of the CancerMath tool using Singapore Malaysia hospital based breast cancer registry data.

Their finding is valid: CancerMath is suitable in general, but not suitable for patients with poor prognosis.

However, we know that CancerMath was built up using data from the US SEER registry, and the majority of the people in the SEER database were not Asian, but Caucasian or African American. So it won't be a surprise to find that CancerMath is not totally suitable for a different ethnic group, such as those in Southeast Asia. I would suggest that the authors add more background information on the percentage of different ethnic groups in the SEER database, and that is the main reason why CancerMath is not completely suitable for Asian people.

Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal